Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment‐resistant depression: A double‐blind, randomized, placebo‐controlled trial.
Saved in:
| Title: | Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment‐resistant depression: A double‐blind, randomized, placebo‐controlled trial. |
|---|---|
| Authors: | Ohtani, Yohei (AUTHOR), Tani, Hideaki (AUTHOR), Nomoto‐Takahashi, Kie (AUTHOR), Yatomi, Taisuke (AUTHOR), Yonezawa, Kengo (AUTHOR), Tomiyama, Sota (AUTHOR), Nagai, Nobuhiro (AUTHOR), Kusudo, Keisuke (AUTHOR), Honda, Shiori (AUTHOR), Moriyama, Sotaro (AUTHOR), Nakajima, Shinichiro (AUTHOR), Yamada, Takashige (AUTHOR), Morisaki, Hiroshi (AUTHOR), Iwabuchi, Yu (AUTHOR), Jinzaki, Masahiro (AUTHOR), Yoshimura, Kimio (AUTHOR), Eiro, Tsuyoshi (AUTHOR), Tsugawa, Sakiko (AUTHOR), Ichijo, Sadamitsu (AUTHOR), Fujimoto, Yu (AUTHOR) |
| Source: | Psychiatry & Clinical Neurosciences. Dec2024, Vol. 78 Issue 12, p765-775. 11p. |
| Subjects: | Japanese people, Mental depression, Asians, Body mass index, Demographic characteristics, Ketamine abuse |
| Abstract: | Aim: Although the antidepressant effect of ketamine on treatment‐resistant depression (TRD) has been frequently reported in North American and European countries, evidence is scarce among the Asian population. We aimed to evaluate the efficacy and safety of intravenous ketamine in Japanese patients with TRD. Methods: In this double‐blind randomized placebo‐controlled trial, 34 Japanese patients with TRD were randomized to receive either intravenous ketamine (0.5 mg/kg) or placebo, administered over 40 min, twice a week, for 2 weeks. The primary outcome was the change in the Montgomery Åsberg Depression Rating Scale (MADRS) total score from baseline to post‐treatment. Secondary outcomes included changes in other depressive symptomatology scores and remission, response, and partial response rates. We also examined the association between baseline clinical demographic characteristics and changes in the MADRS total score. Results: Intention‐to‐treat analysis indicated no significant difference in the decrease in MADRS total score between the groups (−8.1 ± 10.0 vs −2.5 ± 5.2, t[32] = 2.02, P = 0.052), whereas per‐protocol analysis showed a significant reduction in the ketamine group compared to the placebo group (−9.1 ± 10.2 vs −2.7 ± 5.3, t[29] = 2.22, P = 0.034). No significant group differences were observed in other outcomes. Adverse events were more frequent in the ketamine group than in the placebo group, and no serious adverse events were reported. A higher baseline MADRS total score and body mass index were associated with a greater reduction in the MADRS total score. Conclusion: Intravenous ketamine outperformed placebo in Japanese patients with TRD who completed the study, suggesting that ketamine could alleviate depressive symptoms of TRD across diverse ethnic populations. [ABSTRACT FROM AUTHOR] |
| Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Aim: Although the antidepressant effect of ketamine on treatment‐resistant depression (TRD) has been frequently reported in North American and European countries, evidence is scarce among the Asian population. We aimed to evaluate the efficacy and safety of intravenous ketamine in Japanese patients with TRD. Methods: In this double‐blind randomized placebo‐controlled trial, 34 Japanese patients with TRD were randomized to receive either intravenous ketamine (0.5 mg/kg) or placebo, administered over 40 min, twice a week, for 2 weeks. The primary outcome was the change in the Montgomery Åsberg Depression Rating Scale (MADRS) total score from baseline to post‐treatment. Secondary outcomes included changes in other depressive symptomatology scores and remission, response, and partial response rates. We also examined the association between baseline clinical demographic characteristics and changes in the MADRS total score. Results: Intention‐to‐treat analysis indicated no significant difference in the decrease in MADRS total score between the groups (−8.1 ± 10.0 vs −2.5 ± 5.2, t[32] = 2.02, P = 0.052), whereas per‐protocol analysis showed a significant reduction in the ketamine group compared to the placebo group (−9.1 ± 10.2 vs −2.7 ± 5.3, t[29] = 2.22, P = 0.034). No significant group differences were observed in other outcomes. Adverse events were more frequent in the ketamine group than in the placebo group, and no serious adverse events were reported. A higher baseline MADRS total score and body mass index were associated with a greater reduction in the MADRS total score. Conclusion: Intravenous ketamine outperformed placebo in Japanese patients with TRD who completed the study, suggesting that ketamine could alleviate depressive symptoms of TRD across diverse ethnic populations. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13231316 |
| DOI: | 10.1111/pcn.13734 |
